DexCom (DXCM) and Steris (STE) on Torvanta's measures: DXCM grades higher on 3 of the 4 factor families and STE on 1.
| DXCM | STE | |
|---|---|---|
| Value grade | C- | C |
| Growth grade | A | C+ |
| Profitability grade | B+ | C |
| Momentum grade | B- | D+ |
| Market value | $32.5B | $21.7B |
| P/E (trailing) | 34.1x | 27.2x |
| Forward P/E (Torvanta model estimate) | Subscribers | Subscribers |
| Revenue, last 12 months | $5.0B | $6.0B |
| Revenue growth (y/y) | +16% | +8% |
| Operating margin | 22.9% | 18.9% |
| Return on invested capital | 58.7% | 9.8% |
| Free-cash-flow yield | 4.3% | 4.3% |
| Total return, 1 year | +29.7% | -6.3% |
| Total return, 3 years | +9.0% | +2.5% |
Full DXCM analysis · Full STE analysis
DexCom (DXCM) and Steris (STE) on Torvanta's measures: DXCM grades higher on 3 of the 4 factor families and STE on 1. Which fits an investor depends on their goals; this is research, not a recommendation. Subscribers see where the model ranks each and its expected return.
On trailing earnings DXCM trades at 34.1x and STE at 27.2x; their value grades are C- and C against their sectors.
Subscribers get a rating, a fair value estimate, a 12-month target and a risk read for every S&P 500 company, Torvanta's earnings estimates, and three model portfolios (Active, Adaptive and Patient) with every trade sized and explained. A free account includes 3 full Stock Analyst reports a month.
See plans Or get the free weekly newsletterTorvanta is research only - not investment advice and not a recommendation to buy or sell any security. Grades describe a company's reported data against its sector; they are not the model's view, change as data changes and can be wrong. Financial figures come from the company's SEC filings; returns include reinvested dividends. Past performance does not predict future results.
All stock ratings · Stock lists · AI stock research · Model portfolio · Research · Disclaimer